Instil Bio, Inc. Financing Cash Flow
Instil Bio, Inc. (TIL) reported Financing Cash Flow of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Instil Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $378.00K, a 137.74% increase year-over-year.
- Instil Bio, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $7.29M, a 315.50% increase from fiscal 2024.
- Instil Bio, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $1.75M, a 78.29% decline from fiscal 2023.
- Instil Bio, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $8.08M, a 88.76% decline from fiscal 2022.
- Instil Bio, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $71.89M, a 81.72% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $378.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $378.00K derived: sum of 3 quarters · filed 2026-05-15 | $7.06M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $378.00K derived: sum of 2 quarters · filed 2026-03-27 | $7.06M derived: sum of 3 quarters · filed 2026-08-13 | $7.29M 10-K · filed 2026-03-27 |
| 2025-09-30 | $378.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $7.06M derived: sum of 2 quarters · filed 2026-08-13 | $7.29M 10-Q · filed 2025-11-13 | $8.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $6.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.91M 10-Q · filed 2026-08-13 | $8.51M derived: sum of 3 quarters · filed 2026-08-13 | $8.67M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $232.00K 10-Q · filed 2026-05-15 | $1.83M derived: sum of 2 quarters · filed 2026-05-15 | $1.99M derived: sum of 3 quarters · filed 2026-05-15 | $1.99M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.75M derived: sum of 2 quarters · filed 2026-03-27 | $1.75M derived: sum of 3 quarters · filed 2026-03-27 | $1.75M 10-K · filed 2026-03-27 |
| 2024-09-30 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $159.00K derived: sum of 2 quarters · filed 2025-11-13 | $159.00K 10-Q · filed 2025-11-13 | $159.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $0.00 derived: sum of 3 quarters · filed 2025-08-13 | -$587.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-05-13 | -$587.00K derived: sum of 3 quarters · filed 2025-05-13 | $3.62M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$587.00K derived: sum of 2 quarters · filed 2025-03-04 | $3.62M derived: sum of 3 quarters · filed 2025-03-04 | $8.08M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$587.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.62M derived: sum of 2 quarters · filed 2024-11-13 | $8.08M 10-Q · filed 2024-11-13 | $14.28M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $8.67M 10-Q · filed 2024-08-13 | $14.87M derived: sum of 3 quarters · filed 2024-08-13 | $29.59M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $4.47M 10-Q · filed 2024-05-10 | $10.67M derived: sum of 2 quarters · filed 2024-05-10 | $25.39M derived: sum of 3 quarters · filed 2024-05-10 | $76.02M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $20.92M derived: sum of 2 quarters · filed 2024-03-21 | $71.55M derived: sum of 3 quarters · filed 2024-03-21 | $71.89M 10-K · filed 2024-03-21 |
| 2022-09-30 | $14.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $65.35M derived: sum of 2 quarters · filed 2023-11-13 | $65.68M 10-Q · filed 2023-11-13 | $65.88M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $50.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $50.96M 10-Q · filed 2023-08-14 | $51.16M derived: sum of 3 quarters · filed 2023-08-14 | $51.28M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $338.00K 10-Q · filed 2023-05-11 | $536.00K derived: sum of 2 quarters · filed 2023-05-11 | $657.00K derived: sum of 3 quarters · filed 2023-05-11 | -$1.20M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $319.00K derived: sum of 2 quarters · filed 2023-03-31 | -$1.54M derived: sum of 3 quarters · filed 2023-03-31 | $393.16M 10-K · filed 2023-03-31 |
| 2021-09-30 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.74M derived: sum of 2 quarters · filed 2022-11-14 | $392.97M 10-Q · filed 2022-11-14 | $526.04M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $392.85M 10-Q · filed 2022-08-12 | $525.92M derived: sum of 3 quarters · filed 2022-08-12 | $526.03M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $394.70M 10-Q · filed 2022-05-16 | $527.78M derived: sum of 2 quarters · filed 2022-05-16 | $527.89M derived: sum of 3 quarters · filed 2022-05-16 | $707.75M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $133.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $133.19M derived: sum of 2 quarters · filed 2022-03-07 | $313.05M derived: sum of 3 quarters · filed 2022-03-07 | $313.05M 10-K · filed 2022-03-07 |
| 2020-09-30 | $114.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $179.98M derived: sum of 2 quarters · filed 2021-11-15 | $179.98M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $179.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $179.86M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |